ImmuPharma (IMM.L) stock price, revenue, and financials

ImmuPharma market cap is £31.3 m, and annual revenue was £81.28 k in FY 2018

£31.3 M

IMM.L Mkt cap, 27-Nov-2020

£81.3 K

ImmuPharma Revenue FY, 2018
ImmuPharma Net income (FY, 2018)-7.2 M
ImmuPharma EBITDA (FY, 2018)-7.9 M
ImmuPharma EBIT (FY, 2018)-8.1 M
ImmuPharma Cash, 31-Dec-20184.9 M
ImmuPharma EV26.5 M

ImmuPharma Income Statement

Annual

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

25.4k63.2k57.1k22.1m32.5k16.8k184.8k76.4k164.8k150.5k81.3k

Revenue growth, %

(59%)

Operating expense total

(1.5m)3.6m4.6m11.8m4.2m(3.8m)3.6m4.6m6.8m7.4m8.2m

EBITDA

(2.0m)(3.5m)(4.5m)10.3m(4.1m)3.9m(4.1m)(4.2m)(3.3m)(4.4m)(6.5m)(7.1m)(7.9m)

EBITDA margin, %

(7683%)(5525%)(7935%)47%(12746%)23049%(1799%)(5813%)(3925%)(4716%)(9777%)

EBIT

(14.6k)(28.8k)1.5m(3.5m)(4.6m)10.3m(4.2m)3.8m(4.2m)(4.2m)(3.4m)(4.6m)(6.6m)(7.2m)(8.1m)

EBIT margin, %

6036%(5582%)(8009%)47%(12875%)22770%(1853%)(5972%)(3999%)(4808%)(9941%)

Pre tax profit

2.4k16.6k(2.5m)(3.3m)4.9m9.1m(2.5m)(3.6m)(4.2m)(4.4m)(3.3m)(4.5m)(6.3m)(7.0m)(8.0m)

Income tax expense

(1.0k)(1.6k)788.0253.2k(186.2k)(997.4k)495.3k257.5k324.2k744.5k468.7k651.0k990.4k774.2k748.6k

Net Income

1.4k15.1k(2.5m)(3.1m)4.7m8.1m(2.0m)(3.4m)(3.8m)(3.7m)(2.9m)(3.9m)(5.3m)(6.2m)(7.2m)

ImmuPharma Balance Sheet

Annual

GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.01.01.0978.2k1.0m2.7m2.9m12.5m22.5m15.6m12.2m8.9m5.4m5.4m833.4k1.9m2.7m4.9m

Accounts Receivable

3.2k22.2k2.8k13.2k

Current Assets

1.01.01.0979.9k1.0m2.9m3.3m12.6m23.9m16.8m13.5m9.8m6.5m6.1m2.4m6.0m4.4m6.0m

PP&E

12.0k12.8k13.3k9.3k76.8k125.4k114.8k97.1k366.4k280.1k231.9k161.4k164.7k

Goodwill

602.1k560.5k522.5k

Total Assets

1.01.01.0979.9k1.0m3.6m4.1m13.4m24.6m17.6m14.3m10.5m7.2m7.1m3.2m6.7m5.0m8.7m

Accounts Payable

264.0k137.1k366.6k3.8m389.1k471.1k294.4k433.8k386.6k637.9k600.3k753.4k719.9k

Current Liabilities

1.5k13.7k1.1m703.7k1.4m6.1m810.6k946.1k1.1m1.0m991.0k1.2m929.3k1.1m1.0m

Non-Current Liabilities

403.6k345.5k776.1k425.7k771.2k827.1k1.0m769.6k376.0k281.0k234.5k313.3k22.5k

Total Debt

277.9k173.6k776.02.2k1.2k4.7k26.9k974.0891.01.7k142.4k98.3k

Total Liabilities

1.5k13.7k1.1m1.0m2.2m6.6m1.6m1.8m2.1m1.8m1.4m1.5m1.2m1.4m1.0m

Common Stock

1.01.01.0420.0k420.0k6.8m7.3m7.7m8.1m8.2m8.2m8.2m8.2m8.9m8.9m12.5m13.3m13.9m

Retained Earnings

(7.2m)(10.1m)(14.0m)(19.3m)(25.6m)(32.8m)

Total Equity

1.01.01.0978.4k993.4k2.5m3.1m11.2m18.1m16.0m12.5m8.4m5.4m5.7m1.7m5.5m3.6m7.6m

Debt to Equity Ratio

0.1 x0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1 x1 x1 x1 x1 x1.4 x1.3 x1.2 x1.4 x1.1 x1.1 x1.2 x1.3 x1.2 x1.9 x1.2 x1.4 x1.1 x

ImmuPharma Cash Flow

Annual

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

1.4k15.1k(2.5m)(3.1m)4.7m8.1m(2.0m)(3.4m)(3.8m)(3.7m)(2.9m)(3.9m)(5.3m)(6.2m)(7.2m)

Cash From Operating Activities

15.8k18.3k879.6k3.8m(3.6m)12.0m(6.8m)(3.4m)(3.3m)(3.9m)(2.5m)(4.1m)(6.5m)(4.4m)(4.7m)

Cash From Financing Activities

977.0k3.0m(77.6k)12.0m(143.5k)555.2k165.3k356.9k191.5k3.0m(310.1k)7.4m5.4m9.1m

Net Change in Cash

978.2k27.1k2.7m3.7m8.5m11.9m(6.4m)(3.2m)(2.8m)(3.7m)199.0k(4.5m)896.3k945.9k2.3m

Income Taxes Paid

744.5k468.7k651.0k

ImmuPharma Ratios

GBPFY, 2001

Financial Leverage

1 x